Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia

Kathrin M. Bernt and Stephen P Hunger*

Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO, USA

The 1(9;22)(q34;q11) or Philadelphia chromosome creates a BCR–ABL1 fusion gene encoding for a chimeric BCR–ABL1 protein. It is present in 3–4% of pediatric acute lymphoblastic leukemia (Ph+ ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph+ ALL was associated with a very poor prognosis despite the use of intensive chemotherapy and frequently hematopoietic stem-cell transplantation (HSCT) in first remission. The development of TKIs revolutionized the therapy of Ph+ ALL. Addition of the first generation ABL1 class TKI imatinib to intensive chemotherapy dramatically increased the survival for children with Ph+ ALL and established that many patients can be cured without HSCT. In parallel, the mechanistic understanding of Ph+ ALL expanded exponentially through careful mapping of pathways downstream of BCR–ABL1, the discovery of mutations in master regulators of B-cell development such as IKZF1 (Ikaros), PAX5, and early B-cell factor (EBF), the recognition of the complex clonal architecture of Ph+ ALL, and the delineation of genomic, epigenetic, and signaling abnormalities contributing to relapse and resistance. Still, many important basic and clinical questions remain unanswered. Current clinical trials are testing second generation TKIs in patients with newly diagnosed Ph+ ALL. Neither the optimal duration of therapy nor the optimal chemotherapy backbone are currently defined. The role of HSCT in first remission and post-transplant TKI therapy also require further study. In addition, it will be crucial to continue to dig deeper into understanding Ph+ ALL at a mechanistic level, and translate findings into complementary targeted approaches. Expanding targeted therapies hold great promise to decrease toxicity and improve survival in this high-risk disease, which provides a paradigm for how targeted therapies can be incorporated into treatment of other high-risk leukemias.

Keywords: acute lymphoblastic leukemia, BCR–ABL1, tyrosine kinase inhibition, chemotherapy, hematopoietic stem-cell transplantation

Pharmacologic inhibition of the tyrosine kinase activity of BCR–ABL1 is the poster child for molecularly targeted cancer therapy. The first tyrosine kinase to be targeted, it is still the most effective "novel" therapeutic strategy to date, leading to remissions and possibly cures with single agents in chronic myeloid leukemia (CML) (1). Single-agent tyrosine kinase inhibition has not produced sustained responses in Ph+ ALL, but in combination with standard chemotherapy has revolutionized therapy and outcome for this patient population (2).

THE BIOLOGY OF PHILADELPHIA CHROMOSOME-POSITIVE ALL

BCR–ABL1 translocations are associated with two distinct clinical hematologic malignancies, CML and ALL. For CML, three discrete clinical stages have been defined: chronic phase, accelerated phase, and blast crisis. Genomic instability, the accumulation of additional cytogenetic (trisomy 8, isochromosome 17) and molecular (p53 pathway mutations, loss of p16INK4A/ARF) abnormalities, and BCR–ABL1-independent activation of downstream signaling pathways (LYN, AKT, STAT5) are all associated with – and likely contribute to – the progression to blast crisis (3). In about 30% of the cases, the predominant lineage in blast crisis is B-lymphoid rather than myeloid, speaking to the likely hematopoietic stem-cell origin of the disease. This presumed stem-cell origin may also explain the inability to achieve any durable remissions using conventional chemotherpay. Prior to the advent of tyrosine kinase inhibition, temporary disease stabilization was often achieved using hydroxyurea, low-dose cytarabine, and/or interferon, but the only curative approach was an allogeneic hematopoietic stem-cell transplantation (HSCT).

In addition to CML, BCR–ABL1 translocations are found in a distinct subtype of ALL, called Ph+ ALL. The clinical presentation is indistinguishable from ALL with other cytogenetic abnormalities, and the diagnosis relies on the presence of the BCR–ABL1 translocation (cytogenetics and FISH) and/or fusion transcript (PCR). Outcomes for Ph+ ALL were exceptionally poor when treated with chemotherapy, and HSCT in first remission was usually considered to be the best therapy (4). The frequency of

Abbreviations: ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; DFS, disease-free survival; EFS, event-free survival; HSCT, hematopoietic stem-cell transplantation; OS, overall survival; Ph+, Philadelphia chromosome positive; TKD, tyrosine kinase domain; TKI, tyrosine kinase inhibitor.
**BCR–ABL1 rearrangement in ALL**

The **BCR–ABL1** rearrangement in ALL increases with age (Figure 1) and has been reported as high as 50% in the elderly. A greater percentage of patients with adverse cytogenetics contributes substantially to the overall worse outcome in adult compared to pediatric ALL (Figure 1).

The first indication that the **BCR–ABL1** fusion protein is indeed the crucial driver of CML came from mouse studies showing that expression of **BCR–ABL1** in the bone marrow causes a CML-like disease (7–9). Studies that utilized a mutant **BCR–ABL1** protein with an inactive tyrosine kinase domain defined the tyrosine kinase activity of ABL1 as absolutely required for transformation (10). This suggested that targeted inhibition of the ABL kinase domain might be an effective therapeutic strategy in **BCR–ABL1**-driven hematologic malignancies. The pioneering work of Brian Druker spearheaded the clinical development of the first tyrosine kinase inhibitor (TKI), Imatinib (11–13). Imatinib gained FDA approval in 2000 and revolutionized CML therapy, converting a near universally fatal disease requiring HSCT into a chronic condition (14). In the years since the initial success of imatinib, second [nilotinib, dasatinib, bosutinib (15–17)] and third [ponatinib (18)] generation ABL1 class TKIs have been developed, which are active against multiple imatinib-resistant **BCR–ABL1** mutants.

Early studies using imatinib as monotherapy in Ph+ ALL were disappointing, with initial responses rapidly progressing to TKI-resistant disease. However, the integration of TKIs into a high-risk ALL chemotherapy backbone fundamentally changed our approach to Ph+ ALL as well. Overall survival (OS) using this strategy more than doubled compared to chemotherapy-only treated historic controls (2), and HSCT is no longer universally recommended for Ph+ ALL. Despite these advances, the survival of Ph+ ALL still lags behind most other cytogenetic subgroups in pediatric ALL. A better understanding of the biology of Ph+ ALL may help to refine therapy and develop rational combinations of targeted agents that will further improve outcomes for patients with this disease.

**THE PHILADELPHIA CHROMOSOME AND BCR–ABL1 FUSION**

Ph+ ALL derives its name from the presence of the Philadelphia (Ph) chromosome, named after the city where it was first described in the leukemia cells of a CML patient by Nowell and Hungerford in 1960 (19). In 1973, Janet Rowley reported that the Philadelphia Chromosome was the der(22) product of the reciprocal t(9;22)(q34;q11.2) translocation (20). The **BCR–ABL1** fusion gene is generated by joining almost the entire coding region of the **ABL1** tyrosine kinase gene (Abelson murine leukemia virus homolog, exons 2–11, chromosome 9) to the breakpoint cluster region (**BCR**) gene on chromosome 22 (21). There are two main regions where breakpoints cluster within the **BCR** gene. The “CML” breakpoint region lies between exons 12 and 16 in a region called the major breakpoint cluster region (M-BCR). Translocations involving the M-BCR produce the larger p210 **BCR–ABL1** protein, which derives its name from its molecular size of 210 kDa. Translocations that occur within the minor “ALL” **BCR** (m-BCR) yield a smaller p190 gene product that retains only the first exon of **BCR**. A rare p230 fusion protein (with a “micro”-**BCR** breakpoint between exons 19 and 20) has also been described. Both p210 and p190 transform primary human and murine bone marrow cells (8, 9, 22). Of the two, the “ALL-type” p190 is the stronger transforming agent (7, 23). About 90% of pediatric Ph+ ALL patients have the classic ALL-type p190 translocation (24) with some variability reported in the literature as CML in B-lymphoid blast crisis can sometimes be hard to distinguish from Ph+ ALL.

Wild type **ABL1** is a ubiquitously expressed but tightly regulated non-receptor tyrosine kinase that is present throughout hematopoietic development, with declining levels during myeloid maturation. It is predominantly located in the cytoplasm in hematopoietic cells, but can shuttle to the nucleus. In the cytoplasm, **ABL1** is found mostly bound to actin, and functions include signaling and modulation of the cytoskeleton. Nuclear **ABL1** has been implicated in cell cycle control. The N-terminus of **ABL1** negatively regulates **ABL1** kinase activity, allowing for tight titration of **ABL1** kinase activity under physiologic conditions.
Loss of the N-terminus as a result of the BCR–ABL1 translocation results in high constitutive kinase activity. Thus loss of this important regulatory domain is a major contributor to ABL1-mediated leukemogenesis (25) [reviewed in Ref. (26)].

The fusion partner of ABL1, BCR, is a complex locus that is transcribed into two major proteins, both with multiple functional domains implicated in a variety of fundamental biological processes. These include G-protein signaling pathways, cytoskeletal organization, growth, and development. The only exon of BCR that is consistently retained in all fusions is exon 1, which encodes a coiled-coil domain facilitating dimerization and autophosphorylation (amino acids 1–63) (27, 28), a docking site for the adaptor protein GRB-2 (phosphorylated tyrosine 177) (28, 29), and a tyrosine kinase domain (amino acids 298–413) (30). The exact role of the BCR-tyrosine kinase domain is unclear, and in a murine model of CML utilizing retroviral introduction of p210 BCR–ABL1 deletion mutants into bone marrow cells, it appeared to be dispensable. On the other hand, the consistent inclusion of the BCR-tyrosine kinase domain in human BCR–ABL1-driven malignancies suggests that it may play a functional role in leukemogenesis (30–32).

**DOWNSTREAM PATHWAYS ACTIVATED BY BCR–ABL1 FUSION PROTEINS**

The molecular consequence of all BCR–ABL1 fusion proteins is a hyperactive ABL1 kinase domain and aberrant phosphorylation of a variety of targets. Activation results from lack of autoinhibition due to loss of the N-terminal regulatory domain of ABL1, and homodimerization and autophosphorylation of the fusion protein (27). The importance of the homodimerization and autophosphorylation for BCR–ABL1 signaling is underscored by promising in vitro results of peptides and small-molecule inhibitors that cause allosteric inhibition of BCR–ABL1 (33–36). BCR–ABL1 kinase activity leads to direct and indirect activation of multiple pathways (37), including PI3K (38), AKT (39–41), MTOR (42, 43), RAS (39, 44), EGFR, MAP-kinase (40, 43, 45), JNK/SAPK (43), JAK1–3 (46), the SRC-family kinases LYN, HCK, and FGR (47), PTPN11, NF-kB, phospholipase C, and, as a common downstream effector of many of these pathways, STAT5 (Figure 3) (46, 48–50). Most of these pathways have been worked out in CML, but the relevant binding sites or kinase domains are preserved in the p190 fusion protein. Activation of JAK1–3 (50) and STAT1, 3, 5, and 6 (48, 50) has been experimentally confirmed for p190. Work in CML suggests that JAK1–3 activation is mediated through the interaction of BCR–ABL1 with cytokine receptors rather than direct phosphorylation (51). On the other hand, JAK2 appears to directly phosphorylate BCR–ABL1 at the critical tyrosine-177 residue and increase BCR–ABL1 protein stability, thus enhancing BCR–ABL1 signaling (52). Another important downstream pathway that has been confirmed specifically in Ph+ ALL is the PI3K–AKT–MTOR pathway. Deletion of PI3K inhibited leukemogenesis in a murine model of p190 Ph+ ALL. A dual PI3K/MTOR inhibitor was effective on Ph+ ALL patient samples (53) and showed synergy with Imatinib (54). The activation of AKT and MTOR signaling also plays a critical role in steroid resistance in ALL (55, 56), and multiple agents targeting the PI3K/AKT/MTOR axis are currently in clinical trials for pediatric ALL [reviewed in Ref. (57)].

Of particular importance appears to be the adaptor proteins GRB-2 (58–60) and GAB-2 (60), which interact with, and participate in the activation of nearly all of the signaling pathways cited above. GRB-2 has been shown to bind phosphorylated tyrosine-177 (Figures 2 and 3). The importance of this interaction is demonstrated by the impaired in vivo leukemogenesis...
Table 1 | BCR–ABL1 downstream and parallel pathways as drug targets.

| Gene        | Evidence for role in BCR–ABL1-driven leukemia                                      | Drug                                  |
|-------------|-----------------------------------------------------------------------------------|---------------------------------------|
| BCR–ABL1    | Allosteric inhibition of homodimerization and autophosphorylation using GNF2 and GNF5 has activity in retroviral BCR–ABL1 mouse models (incl. T315I BCR–ABL1), particularly in combination with TKIs (35, 36) | GNF2, GNF5¹                           |
| GRB-2       | Impaired binding to p210 BCR Tyr117Phe results in complete loss of leukemogenicity in retroviral BCR–ABL1 mouse model (29, 249), knockdown decreases proliferation of BCR–ABL1 transduced human CD34 cells (45). Validated targets: RAS (39), MAPK, AKT (39) |                                      |
| RAS         | Activated in human CD34+ cells after transduction with p210 BCR–ABL1, dependent on Tyr177 (39) | Temsirolimus (rapamycin), MEK162, PD325901 |
| MAPK/MEK    | Increased in response to imatinib (p210 human CD34+ model), MEK-inhibitor reduces proliferation, synergy with imatinib (40). No Mek inhibition currently in trials for leukemia, phase I study of sorafenib in relapsed leukemia completed (Raf-kinase inhibitor, also inh. VEGFR2/PDGFRβ, C79-6, NCT00131989) |                                      |
| PI3K/AKT    | Activated in human CD34+ cells after transduction with BCR–ABL1, dependent on Tyr177, PI3K inhibitor effective in p210 human CD34+ in vivo model (39, 40), Ph⁺ ALL mouse model, and Ph⁺ ALL patient cells (41). Akt activation plays a role in steroid resistance (65). PI3K inhibitors in trials for relapsed leukemia: BKM120, BEZ235, AMG319, idelisib |                                      |
| MTOR        | PI3K–Akt-MTOR pathway activated by BCR–ABL1. Rapamycin (sirolimus) and dual PI3K/MTOR inhibitor effective in vitro on Ph⁺ ALL patient samples and synergy with TKI (54, 171). MTOR has also been implicated in mediating steroid resistance (56). Multiple agents in clinical trials in relapsed/refractory ALL, including TORC1/2 inhibitors (AP23573) for relapsed leukemia | Sirolimus⁴, everolimus temsirolimus TORC1/2 inhibitors |
| JAK1/2/3    | JAK1, 2, 3 and STAT1, 3, 5, 6 are activated in response to BCR–ABL1 signaling in p190 transduced cells, JAK2 also directly phosphorylates BCR–ABL1. JAK2 knockdown and dual JAK2/BCR–ABL1 inhibition impairs CML cell lines in vitro and in xenografts, and CML cells in vitro (52, 249) | Ruxolitinib (Jak1/2)² ONO44580 (Jak2–BCR–ABL1) |
| FRG         | Src-family, required in p210 lymphoid leukemia mouse model, significant redundancy with other family members (47) | Dasatinib⁰ (Src-family + BCR–ABL1) |
| Hck         | Src-family, required in p210 lymphoid leukemia mouse model, significant redundancy with other family members (47) | Dasatinib⁰ (Src-family + BCR–ABL1) |
| Lyn         | Src-family, required in p210 lymphoid leukemia mouse model, significant redundancy with other family members (47) | Dasatinib⁰ (Src-family + BCR–ABL1) |
| ERBB        | Overexpressed in Ph⁺ ALL (56 versus 4.8% of Ph⁻ ALL). Lapatinib synergetic with imatinib and nilotinib (but not dasatinib) on Ph⁺ ALL cell lines (63) | Lapatinib (ERBB/HER2/NEU) |
| BCL6        | Upregulated in response to TKI in Ph⁺ ALL; deletion, dominant negative, or pharmacologic inhibition synergizes with imatinib and nilotinib in mice (188) | RI-BPI, C79 (188, 250, 251) |
| MDR1        | Promoter methylation inversely associated with presence of Ph⁺ (146) |                                      |
| LRP         | Expression increased compared to normal bone marrow (179) |                                      |

Brief summary of pathways implicated in leukemogenesis and resistance in BCR–ABL1-positive leukemia, as well as potential agents targeting the respective pathways. Superscript numbers and alphabets denote inhibitors of pathways in Figure 3. TORC1/2: MTOR activates two major downstream complexes, TORC1 and TORC2, with distinct biological functions. Sirolimus (rapamycin), temsirolimus, and everolimus inhibit TORC1. Newer generation MTOR inhibitors that target both TORC1 and TORC2 are also currently in clinical trials. Italics: compounds in preclinical development.

in murine models of p210BCR-ABL1 constructs with an engineered inactivating mutation of tyrosine-177 (29, 45, 61). Peptide-inhibition of the SH3 domain of the adaptor protein GRB-2 reduced growth and induced apoptosis in the BCR–ABL1-positive K562 cell line (7). Similarly, genetic inactivation of GAB-2 impairs p210BCR-ABL1-mediated transformation in mice (62).

Recently, overexpression of the epidermal growth factor ERBB was found to be specifically elevated in Ph⁺ ALL (56 versus 4.8% of Ph⁻ ALL) (63). The molecular details of how this pathway intersects with BCR–ABL1 signaling requires further study; preliminarily, p70S6 kinase (MTOR target) has been implicated. From a translational perspective, the ERBB/HER2/NEU inhibitor lapatinib was synergistic with imatinib and nilotinib (but not dasatinib) on Ph⁺ ALL cell lines.

The reported activation of the SCR-family kinases Lyn, Hck, and Fgr by BCR–ABL1 has important implications. BCR–ABL1 has been shown to interact with and activate SRC-family kinases, and inhibition of SRK-family kinases decreased growth and

--
survival of BCR–ABL1-positive myeloid cell lines in vitro (64–71). In addition to being activated by BCR–ABL1, the Src-family kinases Lyn (72) and Hck (73) have been reported to in turn phosphorylate BCR–ABL1 at several sites, including the critical residue for the interaction with the adaptor proteins Grb-2 and Gab-2 (Tyrosine-177). Expression of p210BCRABL1 in murine lymphoid progenitors negative for all three kinases (Lyn−/− Hck−/− Fgr−/−) near completely prevented leukemogenesis in a mouse model of Ph+ lymphoid leukemia (47). There was considerable redundancy between Lyn, Hck, and Fgr in this model, and genetic inactivation of at least two kinases was required to protect mice from leukemia.

Somewhat surprisingly, given that CML cell lines responded to Src inhibition in vitro (67–71), Lyn, Hck, and Fgr were not required to induce CML in vivo (47). A small-molecule inhibitor of SRC-family kinases improved the survival of mice with lymphoid but not myeloid leukemia. Lack of inhibition of Src-family kinases by imatinib, and dual inhibition of Src-kinases and BCR–ABL1 with dasatinib were proposed to underlie the improved efficacy of this combination in comparison to imatinib alone (74). In normal physiologic conditions, Lyn−/− Hck−/− Fgr−/− mice display defects in B-cell maturation and autoimmune features suggest a specific role for these kinases in B-cell development, but the early B-cell compartments appear to be preserved (47). Dependency of Src-family kinases may thus be a specific feature of Ph+ ALL. This is highly relevant from a clinical–translational standpoint as it provides a compelling rationale to investigate the dual BCR–ABL1–SRC-family kinase inhibitor dasatinib in Ph+ ALL, and suggests that this agent may be more effective in Ph+ ALL than imatinib or nilotinib.

Many of these downstream pathways – particularly the JAK–STAT pathway, are also targeted by several newly described leukemic fusion proteins that induce a disease similar to Ph+ ALL, but without a BCR–ABL1 rearrangement. These “Ph-like” leukemias share with Ph+ ALL a transcriptional signature indicative of kinase activation, co-occurring mutations in the B-cell transcription factor IKZF1, and a poor outcome. Initially identified based solely on transcription profiling, improved molecular techniques have allowed identification of a tyrosine kinase mutation in many of these patients. These include rearrangements of JAK2, ABL1, PDGFRB, CRLF2, and EPO receptor, deletion of SH2B3 encoding the JAK2-negative regulator LNK, and activating mutations of FLT3 and the IL7 receptor (IL7R) (75, 76). The presence of these mutations opens the door for potential therapeutic impact using targeted inhibitors (77). This fascinating subgroup of ALL is the topic of a dedicated review in this issue.

DIFFERENCES BETWEEN p210 AND p190 – LESSONS FROM MOUSE MODELS

As mentioned earlier, p190BCR-ABL1 has stronger transforming activity than p210BCR-ABL1 both in fibroblast transforming assays (78) and in mouse models (7, 79). One possible reason may be a higher specific kinase activity and possibly broader substrate range of the p190BCR-ABL1 fusion protein (78). In transgenic animals, p190BCR-ABL1-induced exclusively B-lymphoid leukemia with a short latency, while p210BCR-ABL1 led to development of both lymphoid and myeloid leukemias with a longer latency (79). When introduced into stem cell and progenitor enriched mouse bone marrow, both p210BCR-ABL1 and p190BCR-ABL1 cause a myeloproliferative disease with expansion of granulocytic, myelomonocytic, and lymphoid compartments; however, the disease induced by p190BCR-ABL1 has a significantly shorter latency (7). p190BCR-ABL1 induces stronger STAT1 and STAT3 phosphorylation in Baf3 cells than p210BCR-ABL1 (48), and also induces phosphorylation of STAT6 (50).

CO-OCCURRING GENETIC ABNORMALITIES

Next generation sequencing studies have revealed that many leukemia genomes are remarkably stable – particularly when compared to epithelial cancers. Nevertheless, Ph+ ALL cells have been shown to carry several recurrent mutations that commonly co-occur with BCR–ABL1 fusions and contribute to leukemogenesis. The most frequent co-occurring genetic abnormalities are deletions of the lymphoid-specific transcriptional regulators IKAROS (IKZF1), PAX5 (paired box 5), and EBF1 (early B-cell factor 1). Deletions involving CDKN2A/B are also common. In addition, one of the first examples of “convergent clonal evolution” within the same leukemia was described in Ph+ ALL: one patient’s leukemia contained two cytogenetically distinct subclones that independently acquired a duplication of 8q, corroborating the crucial role of co-occurring mutations (80). Interestingly, GWAS studies have identified genetic polymorphisms of IKZF1 (81–87), PAX5 (88), and CDKN2A/B (81, 89–91) as susceptibility loci that mediate a genetic predisposition to childhood ALL. However, subgroup analysis, when performed, revealed no specific association with Ph+ ALL. This may in part be due to a low number of Ph+ ALL patients in these studies, and a targeted evaluation of IKZF1, PAX5, and CDKN2A/B susceptibility alleles specifically in Ph+ ALL patients may be warranted.

IKZF1 DELETIONS AND POINT MUTATIONS IN PH+ ALL

A review of BCR–ABL1 in ALL requires discussion of its most frequent partner in crime, IKZF1 (86). BCR–ABL1 and IKZF1 mutations are strongly linked: about 70–80% of Ph+ ALLs have somatic mutations in IKZF1 (about 90% deletions and 10% point mutations), which is much higher than the rate of IKZF1 mutations in Ph− ALL (92–94). There are three functional types of IKZF1 mutations: haploinsufficiency or near haploinsufficiency (due to monoallelic null mutations such as inactivating point mutations, premature stop codons, and deletions, 55%), complete absence of Ikaros due to bi-allelic deletions (12%) (92, 93, 95), and alterations that create a dominant-negative (DN) form of Ikaros, Ik6 (33% of all IKZF1 mutations). The Ik6 Ikaros mutant is produced by an in-frame deletion of exons 4–7, which deletes the DNA-binding domain and leads to cytosolic accumulation of the mutant protein (92, 96, 97). The resulting hematopoietic phenotype in a mouse model mimicking this mutation (a smaller deletion that phenocopies the loss of the DNA-binding and nuclear export) is more severe than monoallelic null mutations, as Ik6 associates with the wild type Ikaros and probably traps it in the cytoplasm together with other complex members such as Helios, Aiolos, and Eos (98). The mutations associated with a more profound reduction in Ikaros function (bi-allelic deletion and Ik6) are particularly common in Ph+ ALL (92, 93, 95–97). This underscores the remarkably tight link between Ikaros and PAX5.
According to this model, leukemogenesis (95, 100, 101). There are also reported cases of clones within the same patient carrying different BCR–ABL1 fusion is the first hit, and IKZF1 mutations occur later during leukemogenesis (95, 100, 101). There are also reported cases of “convergent” evolution of IKZF1 mutations, with different subclones within the same patient carrying different IKZF1 mutations, underscoring the importance of this locus for Ph+ ALL (72, 80, 101). Much work has been dedicated to understanding the molecular mechanism of loss of Ikaros alone and in the context of Ph+ ALL. Complete loss or expression of DN Ikaros in normal hematopoiesis causes a mild (Ikaros−/−) to severe (DN) reduction in the number of hematopoietic stem cells (HSC), complete loss of the B-cell and dendritic cell compartments, a skewing toward the T-lymphoid lineage (98, 102–108), and ultimately T-cell malignancies in mice (109). Despite this, IKZF1 mutations are much more common in B-lymphoid than in T-lymphoid malignancies (110). On the surface, the combination of BCR–ABL1 fusion and loss of IKZF1 neatly fits the paradigm proposed by Gilliland for acute myeloid leukemia (AML), which hypothesized that leukemia development requires a combination of class I (signal transduction pathway mutation leading to uncontrolled growth, such as FLT3, or RAS), and class II mutations (aberrant transcription factors resulting in differentiation block, such as PML–RAR, AML–ETO, MLL-translocations, or point mutations in C/EBPα) (111). According to this model, BCR–ABL1 is the class I mutation and IKZF1, the class II mutation. A possible reason for the frequent occurrence of at least the Iκ6 mutation in B-cell precursor ALL could lie in the fact that the exons 4 and 7 are flanked by genomic regions that can function as off-target sites for recombination activated gene (RAG) proteins, which mediate VDJ recombination in this cell population (93, 112). Whether the particularly common co-occurrence of BCR–ABL1 and Iκ6 is solely a function of the developmental stage of the cell of origin, or whether the presence of the BCR–ABL1 translocation predisposes to aberrant RAG activity is not known. In addition, if and how BCR–ABL1 and mutant Ikaros cooperate on a molecular level is still not fully understood. The normal function of Ikaros suggests that one of its main contributions to B-cell leukemogenesis is a differentiation block in the B-lymphoid lineage at the pro- to pre-B-cell stage (122–124). While complete loss of Ikaros results in a complete absence of the entire B-cell compartment, a severely reduced expression of Ikaros allows development up to the Pro- to B-cell stage but not beyond (113). However, additional mechanisms likely play a role. Ikaros has been shown to downregulate Myc, thus loss of Ikaros may result in increased Myc activity and increased proliferation (114). Gene-expression profiling suggests that IKAROS mutated B-ALL has a more prominent “stem-cell signature” (99, 115), and a larger leukemia initiating cell pool [LIC, defined by CD34 expression rather than functionally (96)], suggesting that some of the functions of Ikaros in silencing stem-cell programs in HSCs may play a role (105, 116). Finally, it has been suggested that loss of Ikaros may either synergize with or enhance Jak–Stat signaling. This hypothesis is mostly based on the circumstantial evidence that the other main subtype of ALL with frequent IKZF1 mutations are the Ph-like leukemias. Ph-like leukemias share a transcriptional profile with Ph+ ALL and frequently carry mutations that, like BCR–ABL1, activate Stat5 (75, 117). Modulation of this pathway could both provide a competitive advantage at a subclonal level of IKZF1− clones, and provide an escape pathway for BCR–ABL1 inhibition. Loss of Ikaros predicts a poor prognosis even within Ph+ ALL (94, 99).

PAX5 MUTATIONS IN PH+ ALL

Recurrent mutations of PAX5 occur in about one-third of B-ALL cases (99, 118, 119), and in up to 50% of Ph+ ALL (92, 120, 121). PAX5 is a transcription factor that is expressed specifically during B-cell development, and controls lineage identity and commitment (107, 122). Like loss of Ikaros, loss of PAX5 leads to a differentiation block at the pre-pro- to pre-B-cell stage (122–124). Loss of PAX5 also allows trans-differentiation of already lineage-committed pro-B cells into other lineages, confers a certain degree of self-renewal onto this population (125, 126), and can cause B-cell lymphomas (127). Unlike Ikaros, however, the physiologic expression of PAX5 is limited to B-cell precursor stages, and its loss is not associated with an adverse prognosis (99, 120, 121). It has been speculated that a lack of an effect of PAX5 on hematopoietic stem-cell transcriptional programs may be responsible for the different prognostic implications of PAX5 and IKZF1 mutations (120, 128). In addition to driving B-lymphoid development, Ikaros has been reported to repress hematopoietic stem-cell specific gene-expression programs during early lineage specification, a function not shared with the other two major regulators of B-cell development that are found mutated in Ph+ ALL, PAX5, and EBF1 (Figure 4) (105, 116, 128).

EBF1 MUTATIONS IN PH+ ALL

Early B-cell factor 1 is the predominant transcription factor mediating B-cell lineage commitment (107). It has been shown to co-regulate target genes with PAX5. In mouse models, complete loss of Ebf1 leads to a differentiation block at the pre-pro–B-cell stage (129). In contrast to Ikaros and PAX5, Ebf1−/− mice do not develop spontaneous hematologic malignancies (129). However, combining loss of one allele of Ebf1 or Pax5 with a constitutively active Stat5 allele (the downstream effector in both Ph+ and Ph-like ALL) results in B-cell precursor leukemia in all animals (130). EBF1 mutations occur in about 14% of Ph+ ALL.

CDKN2A/B IN PH+ ALL

The CDKN2A/B locus is frequently altered in ALL. The products of the CDKN2A and CDKN2B genes, p16INK4A and p15INK4B, are inhibitors of cyclin-dependent kinases. In addition, transcription of an alternate reading frame of the CDKN2A locus produces p14ARF, which antagonizes the p53 ubiquitin ligase, HDM2. Silencing of the CDKN2A/B locus in HSC has been implicated in HSC self-renewal (131–134). The distribution of CDKN2A/B alterations within cytogenetic subgroups is non-random. CDKN2A/B is rarely deleted in ALL with translocations of E2A [E2A–PBX1 in t(1;19)(q23;p13) and E2A–HLF in t(17;19)(q21–22;p13) ALL] (135). In contrast, increased rates of
CDKN2A/B deletions are found in Ph\textsuperscript{+} ALL with a reported frequency of ~50% (80, 92, 136) compared to around 30% in non-Ph\textsuperscript{+} B-ALL (137, 138). CDKN2A/B deletions are rare in CML in chronic phase but frequently associated with the transformation to lymphoid blast crisis, suggesting a specific role in B-lymphoid leukemia (139). Similar to IKZF1, the mechanism of deletion of p16 in lymphoid malignancies may involve RAG-mediated recombination (140). Experimental overexpression of BCR–ABL1 induces expression of Arf, which, if unopposed, leads to apoptosis (141). Introduction of p190\textsubscript{BCR–ABL1} into Arf-null murine bone marrow decreases the latency and increases resistance to imatinib in the lymphoid malignancy that develops in recipient mice. In most clinical studies that have assessed the prognostic significance of CDKN2A/B loss of function in ALL, CDKN2A/B deletion or hypermethylation do not appear to be associated with changes in outcome for pediatric ALL, while silencing or inactivation of the locus predicts a worse outcome in adults (99, 136, 138, 142–146). In a recent study mapping clonal evolution in adult patient-derived Ph\textsuperscript{+} ALL cells grown in immunodeficient mice, the loss of CDKN2A/B was associated with increased competitive advantage on a subclonal level, more aggressive growth in xenografts, a higher leukemia initiating frequency, and a trend toward inferior outcome in patients (80). In both children and adults, deletions as well as epigenetic silencing through promoter hypermethylation are found at increased frequencies in relapsed specimens as opposed to those from initial diagnosis, suggesting a role in mediating relapse and resistance to therapy (147–150).

**EPIGENETIC ABNORMALITIES IN PH\textsuperscript{+} ALL**

In addition to genetic abnormalities, Ph\textsuperscript{+} ALL has a characteristic DNA methylation profile. Ph\textsuperscript{+} ALL can be distinguished from other subtypes of ALL by hierarchical clustering of DNA methylation profiles. A recent study that quantified differentially methylated regions (DMRs) in all major ALL subtypes (compared to B-cell precursors, i.e., using a developmentally matched control) revealed about 350 DMRs in Ph\textsuperscript{+} ALL samples (151). This was remarkably different from only about 50 DMRs identified in CRLF2-rearanged ALL samples, many of which were “Ph-like” ALL samples that share a major transcriptional program with Ph\textsuperscript{+} ALL but are negative for the BCR–ABL1 translocation, and instead commonly have activating Jak1/2 mutations. Whether differential methylation is a consequence of the BCR–ABL1 fusions or co-occurring genetic abnormalities, and whether it plays a role in malignant transformation, resistance or relapse is unknown. However, an active role for DNA methylation in malignant transformation (rather than a mere reflection of the transcriptional landscape) is supported by the dependence of several experimental tumor models on functional DNA methyltransferase Dnmt1 (152, 153), including MLL–AF9 and Myc–Bcl2-driven leukemia (145, 155). Reactivation of silenced CDKN2A/B by demethylating agents may have therapeutic benefit in a subgroup of ALL patients where this locus is intact (148), and demethylating agents are currently in clinical trials for relapsed and refractory ALL. Very little is known about a potential involvement of other epigenetic mechanisms in the biology of Ph\textsuperscript{+} ALL, such as covalent modifications of histones or nucleosome positioning. A better understanding of Ph\textsuperscript{+} ALL biology, including associated genetic and epigenetic abnormalities, should facilitate the development of rational synergistic combinations of targeted agents with TKIs.

**MECHANISMS OF RESISTANCE IN PH\textsuperscript{+} ALL – BCR–ABL1 MUTATIONS**

One of the primary mechanisms of resistance and treatment failure in CML is the acquisition of BCR–ABL1 mutations that render the fusion protein completely or relatively unresponsive to TKIs. A plethora of different mutations mediating imatinib-resistance have been described. Most of these mutant BCR–ABL1 proteins are still sensitive to the second generation ABL kinase inhibitors dasatinib and nilotinib. In addition, the recently approved ponatinib is active against the most common mutation that causes resistance to both first and second generation ABL TKIs, the “gatekeeper” T315I...
Table 2 | Activity (IC50) of imatinib, dasatinib, nilotinib, and ponatinib against selected BCR–ABL1 mutants

| Domain                  | Mutant | Imatinib IC50 (nM) | Dasatinib IC50 (nM) | Nilotinib IC50 (nM) | Ponatinib IC50 (nM) |
|-------------------------|--------|--------------------|---------------------|---------------------|---------------------|
| P-loop                  |        |                    |                     |                     |                     |
|                         | G250E  | 3613               | 8.14                | 80.67               | 4.1                |
|                         | G252H  | 733                | 5.59                | 46.75               | 2.2                |
|                         | Y253F  | 1888               | 2.89                | 57.16               | 2.8 (H: 6.2)       |
|                         | E256K  | 3174               | 10.26               | 118.4               | 14                 |
|                         | E256V  | 8953               | 6.30                | 182.3               | 36                 |
| ATP-binding region      |        |                    |                     |                     |                     |
|                         | T315I  | 9221               | 137.30              | 697.1               | 11 (A: 1.6)        |
|                         | F317L  | 1379               | 8.16                | 39.19               | 1.1 (V: 10)        |
| SH2-binding region      |        |                    |                     |                     |                     |
|                         | M351T  | 926                | 1.61                | 7.804               | 1.5                |
| Substrate-binding site  |        |                    |                     |                     |                     |
|                         | F359V  | 1509               | 2.73                | 91.29               | 10                 |
|                         | H396P  | 1280               | 1.95                | 42.65               | 1.1                |

IC50 of imatinib, dasatinib, and nilotinib was determined side by side in Ba/F3 cells transfected with the indicated BCR–ABL1 mutants (245) and fairly consistent with previously reported IC50 values in single-agent studies (reviewed in Ref. (246)). IC50 values for ponatinib were obtained in a separate experiment (247), therefore, direct comparison should be undertaken with caution (italics). However, the overall lower IC50 and preserved activity against a wide spectrum of BCR–ABL1 mutations, including T315I, can be appreciated.

**Figure 5** | BCR–ABL1TKD mutations. Location of the BCR–ABL1 tyrosine kinase domain mutations listed in Table 2. The T315I mutation, which causes resistance against imatinib, dasatinib, and nilotinib is depicted in red. P-loop: phosphate-binding loop; A-loop: activation loop.

Mutation (Table 2; Figure 5). Kinase domain mutations develop even more frequently in Ph+ ALL treated with TKI monotherapy despite initial sensitivity (156–162) (161, 163, 164). A rate of BCR–ABL1 kinase domain (TKD) mutations of >80% has been reported in (adult) patients with Ph+ ALL at relapse (165–167), with the most common mutations being T315I, Y253H, and E255K/V (42, 168). There has been considerable debate in the field whether these mutations occur during treatment, or whether TKIs select for pre-existing resistant subclones. Several studies suggest that a substantial percentage of patients harbor subclones with TKD mutations prior to the initiation of therapy (42, 169–171). BCR–ABL1 mutations known to cause resistance have been identified in minor subclones in as many as 40% of Ph+ patients at initial diagnosis (169). Tyrosine kinase domain mutations may be less common in patients treated with a combination of intensive chemotherapy and TKI. In addition, the kinetics of emergence of resistant mutants – when they do develop – is not well-studied. Sequencing of 10 evaluable pediatric patients treated with imatinib and highly intensive chemotherapy on AALL0031 revealed two known resistance causing BCR–ABL1 mutations at relapse, none of which were detected in the initial diagnostic sample (38). Both mutations are responsive to nilotinib or dasatinib (M244V and H396P) (53). In contrast, in the GIMEMA LAL1205 study, the T315I mutation was discovered in four out of seven patients who relapsed after induction with dasatinib + steroids only, followed by intensive consolidation (intensive chemotherapy + TKI + auto H SCT, or allo HSCT) (172). It is possible that the combination of TKIs with an up-front intensive chemotherapy backbone serves to reduce selective pressure on TKI-resistant subclones. However, more in depth analysis will be required to define the respective roles of resistance to TKI and standard chemotherapy, and their interdependence. The fact that BCR–ABL1 has been found mutated at relapse also raises the important question how aggressively patients with Ph+ ALL who receive TKIs on a backbone of standard chemotherapy should be screened for the emergence of TKD mutations. Since patients may still respond to the chemotherapy portion, early warning signs of TKI failure may be missing. If resistant mutants develop or emerge with similar kinetics to what is observed with monotherapy, patients may receive months or years of ineffective TKIs only to ultimately relapse, when early detection of an emergent mutant clone could have prompted switching to another agent active against the mutant BCR–ABL1. A major technical difficulty of such studies is the limit of detection to reliably assess and follow clonal heterogeneity in a minimal residual disease (MRD) setting. The decreased cost of sequencing and novel techniques such as MRD-sort combined with high throughput single cell sequencing may be able to provide answers in the near future. However, the complexity and cost of such an approach would first require a more in depth study of whether BCR–ABL1 mutations are a substantial contributor to resistance and relapse in Ph+ ALL treated with intensive chemotherapy plus TKI.

MECHANISMS OF RESISTANCE IN PH+ ALL – INCREASED INTRACELLULAR BCR–ABL1

In addition to kinase domain mutations, increasing the amount of BCR–ABL1 protein in the cell can lead to resistance to TKIs.
One mechanism includes amplification of the BCR–ABL1 fusion gene or the entire Ph+ chromosome, which has been reported in up to 10% of Ph+ ALL (173, 174). Amplification of p210BCR-ABL1 also appears to be particularly common in lymphoid blast crisis of CML (175).

MECHANISMS OF RESISTANCE IN PH+ ALL – OVEREXPRESSION OF DRUG EXPORTERS

There is also evidence for the involvement of drug exporters such as ABCB1/MDR1/PGP and ABCG2/BCRP in the development of TKI resistance in CML (112, 176–178). Less data is available on the role of drug efflux pumps in Ph+ ALL. One study evaluated the expression levels of LRP, MRP, and ABCB1/MDR1/PGP in Ph+ ALL, and found consistent overexpression of LRP, but not MRP and ABCB1/MDR1/PGP (179). In contrast, promoter CpG methylation of MDR1 (i.e., silencing) in ALL was found to be inversely correlated with the presence of the Philadelphia chromosome, suggesting a role for MDR1 in Ph+ ALL as well (146). Overexpression of ABCB1/MDR1/PGP was also found as a mechanism of resistance to nilotinib in CML cell lines (180).

MECHANISMS OF RESISTANCE IN PH+ ALL – UPREGULATION OF PARALLEL PATHWAYS

A large amount of data supports Src-family kinases as a mediator of resistance to imatinib and nilotinib. Src-family kinases are activated downstream of BCR–ABL1, and may play a particularly important role in lymphoid blast crisis and Ph+ ALL (see also “Downstream Pathways Activated by BCR–ABL1 Fusion Proteins”) (47, 64–71, 74). Persistent HCK and LYN activity has been detected in CML patients who failed imatinib despite the absence of a BCR–ABL1 mutation (72, 181, 182). In imatinib-resistant cells, LYN was found in a complex with BCR–ABL1 and GAB-2 (72). LYN and HCK have been shown to be activated by BCR–ABL1 in a non-kinase dependent manner, and are in turn able to phosphorylate BCR–ABL1 (72, 73). Imatinib-resistant CML cell lines or mouse models overexpressing Src-family kinases were shown to respond to the dual BCR–ABL1–Src-family kinase inhibitor dasatinib, but not nilotinib or Imatinib (147).

Another parallel pathway with a potential role in TKI resistance is the JAK–STAT pathway. p190BCR-ABL1 activates JAK1, 2, and 3 and STAT1, 3, 5, and 6, likely providing a positive-feedback loop, substantial signal amplification, and redundancy. A dual BCR–ABL1–JAK2 inhibitor was able to overcome TKI resistance in vivo and a K562 mouse model (52, 183). JAK2 inhibitors are currently in clinical trials for myeloproliferative disorders and AML, and are being explored for Ph-like ALL with JAK mutations (184).

An additional escape pathway involves AKT, STAT5, and the B-cell lymphoma 6 (BCL6) transcriptional repressor. BCL6 is a well-established proto-oncogene in lymphoid malignancies that is a common target of activating translocations in diffuse large B-cell lymphoma (DLCL) (185). STAT5, one of the major downstream targets of the BCR–ABL1 fusion protein, suppresses BCL6 in B-cells (186, 187). In vitro treatment of Ph+ ALL cells was shown to result in about 90-fold upregulation of BCL6 that was dependent on STAT5, to levels similar to those present in DLCLB. In addition, BCL6 is upregulated by FoxO4, which in turn is inactivated by PI3K/AKT signaling. This suggests involvement of both the JAK2/STAT5 and PI3K/AKT signaling pathways in mediating the derepression of BCL6 in response to TKIs. Deletion, expression of a dominant negative, or pharmacologic inhibition of BCL6 synergized with imatinib and nilotinib in syngeneic and primary patient xenograft mouse models (188). The mechanism of BCL6-mediated resistance may include repression of Arf and p53-mediated apoptosis, and the induction of more stem-cell-like features such as quiescence and self-renewal, which may specifically enhance the survival and resistance of LICs (189). Induction of cell cycle exit and quiescence is one of the normal functions of BCL6 during B-cell development at the pre-B stage (190).

The RAS-RAF-MEK–MAPK pathway may also contribute to suboptimal efficacy of BCR–ABL1 inhibitors and resistance (43). MAPK activity was found to be increased in a presumed compensatory response to imatinib treatment of human CD34+ cells transduced with p210BCR-ABL1. A MEK-inhibitor reduced proliferation in this model and showed synergy with Imatinib (40). Finally, overexpression of the epidermal growth factor ERBB/HER2/NEU has been linked to drug resistance in ALL (191). ERBB is frequently elevated in Ph+ ALL, and ERBB/HER2/NEU inhibitor lapatinib was synergistic with imatinib and nilotinib (but not dasatinib) on Ph+ ALL cell lines with high ERBB expression (63).

MECHANISMS OF RESISTANCE IN PH+ ALL – ACQUISITION OF ADDITIONAL GENETIC ABNORMALITIES INTERFERING WITH TRANSCRIPTIONAL REGULATION AND B-CELL DEVELOPMENT

Mutations of IKZF1 play a fundamental role in Ph+ ALL (86). In addition to being extremely common at diagnosis, IKZF1 mutations are further enriched at relapse. This includes both presumed de novo acquisition of an IKZF1 mutation (192, 193), as well as selection for a subclone with a more severe mutation (Iκκ6 or homozygous deletion) at relapse that was initially present at a low percentage (95). This pattern suggests a role for Ikaros in mediating drug resistance and relapse. However, how Ikaros would specifically cause drug resistance is unclear. A potential mechanism could lie in the fact that IKZF1 mutated B-ALL has a more “stem-cell like” signature by gene-expression profiling than IKZF1 wild type B-ALL. HSC are highly drug resistant, and expression of a stem-cell program has been associated with drug resistance and poor outcome in other types of leukemia (194–197).

MECHANISMS OF RESISTANCE IN PH+ ALL – INHIBITION OF APOPTOSIS

As discussed above, increased promoter methylation has been described in relapsed ALL specimens when compared to the initial diagnostic specimen. CDKN2A/B appears to be a key locus that influences to drug resistance and is affected by epigenetic silencing or deletion (137, 142, 143, 146, 148, 151, 198). One of the consequences of deleting or silencing the CDKN2A locus is the inability to upregulate p14Arf, which can lead to a loss of functional p53 through increased activity of the p53 E3 ubiquitin ligase HDM2. Another mechanism of inactivating p53 in Ph+ ALL involves the upregulation of BCL6 discussed above (188). In a murine model of Ph+ ALL, imatinib treatment resulted in BCL6 upregulation and downregulation of p53, while genetic inactivation of BCL6 resulted in increased levels of p53 and failure to cause leukemia in mice. Interestingly, BCL6 was also recruited to the CDKN2A locus.
Dual inhibition of BCR–ABL1 and BCL6 demonstrated in synergy in xenographs of patient-derived primary Ph+ ALL cells. Efficient inactivation of the p53 pathway by BCR–ABL1 and its downstream targets may explain why genetic mutations or deletions of p53 are rare up-front in Ph+ ALL (199, 200). Acquisition of p53 mutations at relapse has been described, but appears a rather rare event compared to the commonly affected IKZF1, PAX5, and CDKN2A/B loci (150, 201–203).

MECHANISMS OF RESISTANCE IN PH+ ALL – RESISTANCE TO CONCOMITANT CHEMOTHERAPEUTIC AGENTS

In addition to resistance to TKIs, resistance to standard chemotherapy agents can develop during treatment with chemotherapy plus TKI. Mechanisms of resistance discussed above – mutation, amplification, or upregulation of the molecular target, drug exporters, the expression of stem-cell signatures, upregulation of survival pathways, and inhibition of apoptosis apply to cytotoxic agents as well (204–206). In addition, several recurrent genetic alterations have been found enriched in ALL at relapse that confer resistance to specific cytotoxic agents. These include loss of MSH6 [mediating resistance to thiopurines, alkylating agents, and prednisone (202)], decreased MSH2 protein levels (mediating resistance to purine analogs) (207), and mutations in NR3C1 and CREBBP (mediating glucocorticoid resistance) (55, 193, 203, 208–211). None of these mechanisms appear to be specific to Ph+ ALL. Finally, the contribution of AKT and MTOR – both are activated in response to BCR–ABL1 signaling – to glucocorticoid resistance has been discussed above (55, 56).

MECHANISMS OF RESISTANCE IN PH+ ALL – INTERACTIONS WITH THE BONE MARROW Niche AND THE IMMUNE SYSTEM

In addition to cell-autonomous mechanisms of resistance, ALL blasts interact with the bone marrow niche (212) and the immune system. Some of these interactions probably contribute to the emergence of resistance and relapse. At the same time, our improved understanding of leukemic blast–host interactions has led to the development of therapeutic approaches that attempt to disrupt the interaction with the bone marrow niche (213, 214), or aim to break tolerance and effectively engage the patient’s immune system in the eradication of leukemia [reviewed in Ref. (206)]. None of these approaches are specifically targeted at Ph+ ALL.

CURRENT CLINICAL CONCEPTS IN THE TREATMENT OF PH+ ALL

INITIAL STUDIES USING IMATINIB

Prior to the use of TKI, survival for pediatric Ph+ ALL treated with chemotherapy with or without HSCT was extremely poor. The International Ponte di Legno Childhood ALL Consortium reported 7-year event-free survival (EFS) and OS rates of 25 and 36% for 326 Ph+ ALL patients diagnosed between 1985 and 1996, and 32 and 45% for 610 Ph+ ALL patients diagnosed between 1995 and 2005 and treated without TKI in first remission (4, 215). Although initial white blood cell count, age, and early response to therapy were predictive of outcome, the EFS even for “good-risk” patients was <50% (4). In the pre-TKI era, HSCT in first remission was generally considered to be the best available treatment option, particularly if a matched related donor was available. While HSCT produced slightly better results than chemotherapy alone, relapse was common even after allogeneic HSCT. In the 1995–2005 era, the 5-year EFS and OS rates for patients who achieved a first remission (89%) and went on to HSCT were only 34.2 and 48.3% (4).

Following the landmark reports showing the efficacy of imatinib in CML, several studies had shown transient single-agent efficacy of imatinib in patients with relapsed or refractory Ph+ ALL, and adult trials had shown the feasibility of combining imatinib with chemotherapy, albeit on an intermittent dosing schedule and typically as a bridge to early HSCT (157, 159, 162). In 2002, the Children’s Oncology Group (COG) began the AALL0031 trial that was designed to evaluate the safety and efficacy of combining imatinib (340 mg/m²/day) with a very intensive chemotherapy regimen (2). Imatinib was introduced after 4-weeks of induction therapy were completed and the exposure was successively increased in five cohorts, with expanded accrual in cohort 5 to estimate efficacy. In cohort 5, patients received continuous imatinib therapy starting at day 1 of consolidation therapy, with intermittent (14 days on – 14 days off) dosing during the last year of maintenance therapy. A parallel cohort of Ph+ ALL patients was treated with the identical chemotherapy regimen, without imatinib. Overall, addition of imatinib to the intensive chemotherapy regimen was tolerated very well, with no significant increase in toxicity of the combined regimen compared to chemotherapy alone. In the initial study report, the 3-year EFS for patients treated in cohort 5 was 80%, as compared to 35% in a historical control group treated in the pre-TKI era (Figure 6) (2). This outstanding outcome has been stable over time with recent analyses showing a 71% 7-year EFS rate for patients in AALL0031 cohort 5 versus 21.4% in the historical control group (Figure 6) (216). AALL0031 also explored the use of HSCT (matched related HSCT for patients on study, the final analysis also included follow-up of patients who went off study for an unrelated-donor HSCT). Neither matched related or unrelated HSCT offered any additional benefit (2, 216). Results of this trial, although based on a relatively small number of patients, revolutionized clinical practice for children and adolescents with Ph+ ALL. Tyrosine kinase inhibition is an integral part of treatment for Ph+ ALL and is now incorporated during induction therapy. HSCT in first remission is no longer routinely recommended for all patients as a default, though it may still be an important treatment for patients that respond poorly to chemotherapy plus TKI.

A key pediatric study conducted primarily in Europe by 10 study groups in parallel to COG AALL0031, was the EsPhALL phase 3 trial (91). Patients received induction therapy according to the standard of their respective study group, and were categorized as good (108 patients) or poor risk (70 patients) based on initial response. The study then randomized good-risk patients to chemotherapy with or without post-induction imatinib on the backbone of the intense Associazione Italiana di Ematologia Oncologica Pediatrica – Berlin–Frankfurt–Münster (AIEOP-BFM) ALL 2000 regimen. Poor-risk patients were all assigned to chemotherapy plus imatinib. HSCT was recommended for all patients, and performed in 77% of patients in this trial. The imatinib exposure was intermittent with much lower cumulative exposure than used on AALL0031 (126 versus 616 days on AALL0031 cohort 5). The EsPhALL trial confirmed the superior efficacy of imatinib plus...
chemotherapy. The 4-year disease-free survival (as treated analysis of 81 patients) was 75.2% for good-risk patients receiving imatinib and 55.9% for those who did not receive imatinib ($p = 0.06$). Outcomes for the poor-risk population were also encouraging with 4-year EFS of 53.5%, which was significantly better than the outcome of historical control patients treated without imatinib. This is the largest, and the only randomized trial to systematically assess imatinib in combination with intensive multi-agent chemotherapy in children with Ph+ ALL. Given the results of this trial and AALL0031, it is highly unlikely that another trial will ever be conducted for chemotherapy with/without TKI in pediatric Ph+ ALL. The EsPhALL trial was amended to start continuous imatinib treatment at day 15 of induction therapy, and decrease the number of patients who underwent HSCT in first remission. This study will accrue patients through early to mid 2014.

A superior outcome with the addition of imatinib to chemotherapy in pediatric Ph+ ALL was also reported by the Sociedad Española de Hematología y Oncología Pediátricas (217). In the SHOP-2005 trial imatinib was initiated on day 15 of induction, and most patients (15/16) underwent bone marrow transplantation in first remission. The 3-year EFS for patients on this trial was significantly higher than that of historical controls who did not receive imatinib (the rate of BMT in the historical control was 17/27).

SECOND GENERATION TKIs (DASATINIB, NILOTINIB)

In light of the encouraging but still suboptimal results obtained with chemotherapy plus imatinib in pediatric Ph+ ALL, and the development of second generation BCR–ABL1 inhibitors, it was logical to investigate whether the use of dasatinib or nilotinib in combination with chemotherapy might further improve outcomes (Table 3). Multiple lines of reasoning suggest that this could be the case. Second generation TKIs are more potent inhibitors of BCR–ABL1 in vitro, and lead to earlier and more profound reduction of the leukemic clone burden in CML (15, 16). The CNS is a well-known sanctuary site in ALL and CNS penetration of imatinib is poor. While very little data are available on the CNS penetration of nilotinib, oral administration of dasatinib produces therapeutic levels in the CSF (218). The imatinib-resistant TKD mutations reported to occur in relapsed Ph+ ALL are typically responsive to dasatinib or nilotinib, with the important exception of the gatekeeper T315I mutation that is resistant to all three agents (38, 53). Finally, multiple other kinases are activated by BCR–ABL1, including PI3K/AKT (39, 40), EGFR, MAP-kinase (40, 45), JNK/SAPK, JAK1–3, and the Src-family kinases LYN, HCK, and FGR (47, 67–71). Particularly Src-kinases appears to be an important downstream target of the BCR–ABL1-induced signaling cascade, while also phosphorylating BCR–ABL1 in a positive-feedback loop, and contributing to clinical resistance against TKIs. This pathway may be particularly important in Ph+ lymphoid malignancies (47, 72, 74, 91, 157, 180–182). Because dasatinib targets both BCR–ABL1 and Src-family kinases, it is a particularly attractive agent to investigate in Ph+ ALL, as it may suppress the BCR–ABL1 signaling cascade at multiple levels. This could result in a more profound inhibition, reduction of the emergence of resistance, and improved clinical outcomes. In contrast to dasatinib, nilotinib does not efficiently inhibit Src-family kinases, and LYN (as well as two other tyrosine kinases that interact with LYN, SYK and AXL) has been implicated in mediating resistance to nilotinib (180, 219).

Dasatinib monotherapy demonstrated encouraging efficacy against adult Ph+ ALL in early clinical trials (220, 221). In the GIMEMA LAL1205 study, 55 patients received induction with dasatinib + steroids and IT-MTX, while post-induction consolidation was at the discretion of the treating center. Two patients received no further therapy and 19 patients continued on TKI only (69.6% relapse at 20 months), 14 patients received intensive chemotherapy + TKI (21.7% relapses), 18 went on to allogeneic HSCT (11.1% relapses) (172). This trial demonstrated impressive remission rates for dasatinib and steroids only, but at the same time underscored the importance of adding intensive chemotherapy and/or HSCT to maintain durable remissions. The encouraging early data led to several trials investigating dasatinib
in combination with chemotherapy. Incorporation of pulses of twice daily dasatinib with hyper-CVAD, followed by continuous dasatinib during maintenance and indefinitely after completion of chemotherapy resulted in a CR rate of 94% and an estimated 2-year survival of 64% (EFS and OS have not yet been reported) (222). The combination of dasatinib with hyper-CVAD using a similar regimen (but with dasatinib given continuous) in adults with relapsed Ph+ ALL was also recently reported (223). Dasatinib ± nilotinib in combination with chemotherapy in newly diagnosed Ph+ ALL patients is currently being studied in a phase Ib trial (NCT01405788) (224). Dasatinib followed by HSCT + continuous dasatinib ± nilotinib has similar activity to dasatinib against imatinib-resistant BCR–ABL1 mutants. However, nilotinib does not inhibit the Src-family kinases, which is theoretically important in Ph+ ALL but has not yet been shown to be clinically important (180, 219). It is not clear whether the CNS penetration of nilotinib is as good as that of dasatinib (218). Nevertheless, nilotinib has shown encouraging activity in adult relapsed/refractory Ph+ ALL, with some patients achieving responses that were sustained for months on monotherapy (225).

The other major second generation TKI is nilotinib, which has similar activity to dasatinib against imatinib-resistant BCR–ABL1 mutants. However, nilotinib does not inhibit the Src-family kinases, which is theoretically important in Ph+ ALL but has not yet been shown to be clinically important (180, 219). It is not clear whether the CNS penetration of nilotinib is as good as that of dasatinib (218). Nevertheless, nilotinib has shown encouraging activity in adult relapsed/refractory Ph+ ALL, with some patients achieving responses that were sustained for months on monotherapy (225).

Published studies on nilotinib therapy in newly diagnosed Ph+ ALL patients are currently collaborating on a study that tests adding dasatinib 60 mg/m²/day to the EsPhALL chemotherapy backbone (COG AALL1122, NCT01406160) and are working together to develop a successor trial that randomizes patients to receive one of two different chemotherapy backbones plus TKI.

The other major second generation TKI is nilotinib, which has similar activity to dasatinib against imatinib-resistant BCR–ABL1 mutants. However, nilotinib does not inhibit the Src-family kinases, which is theoretically important in Ph+ ALL but has not yet been shown to be clinically important (180, 219). It is not clear whether the CNS penetration of nilotinib is as good as that of dasatinib (218). Nevertheless, nilotinib has shown encouraging activity in adult relapsed/refractory Ph+ ALL, with some patients achieving responses that were sustained for months on monotherapy (225).

Published studies on nilotinib therapy in newly diagnosed Ph+ ALL patients are currently collaborating on a study that tests adding dasatinib 60 mg/m²/day to the EsPhALL chemotherapy backbone (COG AALL1122, NCT01406160) and are working together to develop a successor trial that randomizes patients to receive one of two different chemotherapy backbones plus TKI.

The other major second generation TKI is nilotinib, which has similar activity to dasatinib against imatinib-resistant BCR–ABL1 mutants. However, nilotinib does not inhibit the Src-family kinases, which is theoretically important in Ph+ ALL but has not yet been shown to be clinically important (180, 219). It is not clear whether the CNS penetration of nilotinib is as good as that of dasatinib (218). Nevertheless, nilotinib has shown encouraging activity in adult relapsed/refractory Ph+ ALL, with some patients achieving responses that were sustained for months on monotherapy (225).

Published studies on nilotinib therapy in newly diagnosed Ph+ ALL patients are currently collaborating on a study that tests adding dasatinib 60 mg/m²/day to the EsPhALL chemotherapy backbone (COG AALL1122, NCT01406160) and are working together to develop a successor trial that randomizes patients to receive one of two different chemotherapy backbones plus TKI.

The other major second generation TKI is nilotinib, which has similar activity to dasatinib against imatinib-resistant BCR–ABL1 mutants. However, nilotinib does not inhibit the Src-family kinases, which is theoretically important in Ph+ ALL but has not yet been shown to be clinically important (180, 219). It is not clear whether the CNS penetration of nilotinib is as good as that of dasatinib (218). Nevertheless, nilotinib has shown encouraging activity in adult relapsed/refractory Ph+ ALL, with some patients achieving responses that were sustained for months on monotherapy (225).

Published studies on nilotinib therapy in newly diagnosed Ph+ ALL patients are currently collaborating on a study that tests adding dasatinib 60 mg/m²/day to the EsPhALL chemotherapy backbone (COG AALL1122, NCT01406160) and are working together to develop a successor trial that randomizes patients to receive one of two different chemotherapy backbones plus TKI.

The other major second generation TKI is nilotinib, which has similar activity to dasatinib against imatinib-resistant BCR–ABL1 mutants. However, nilotinib does not inhibit the Src-family kinases, which is theoretically important in Ph+ ALL but has not yet been shown to be clinically important (180, 219). It is not clear whether the CNS penetration of nilotinib is as good as that of dasatinib (218). Nevertheless, nilotinib has shown encouraging activity in adult relapsed/refractory Ph+ ALL, with some patients achieving responses that were sustained for months on monotherapy (225).
patients (230). Early results of combining nilotinib with intensive chemotherapy in the current South Korean cooperative trial have also shown excellent activity (231). Nilotinib was given continuously from induction until completion of chemotherapy (2 years). All patients were eligible for HSCT, and 59/91 of patients underwent HSCT in first remission. The complete remission rate was 90% and the 2-year OS 70%.

**TARGETING THE T315I MUTATION: PONATINIB**

Dasatinib and nilotinib are effective against the vast majority of reported BCR-ABL1 TKD mutants with one crucial exception: the T315I mutation. For many years, T315I conferred resistance to all available TKIs. Ponatinib is a multi-targeted TKI with strong activity against BCR-ABL and imatinib-resistant mutants including, for the first time, T315I. Ponatinib gained accelerated approval from the FDA in the US in December 2012 based on very promising activity observed in the PACE II clinical trial, including major cytogenetic responses in 70% of patients with T315I mutations (18). Several other studies have shown promising activity in newly diagnosed CML patients (NCT01570886, NCT01641107, and the EPIC trial NCT01650805), but all of these US trials were halted in October 2013, when a high rate of cardiovascular adverse events was reported in post-approval surveillance. Ponatinib was approved for use in the European Union in July 2013, and remains on the market at this time. As of December 2013, the future of this agent, which is the only agent known to be effective for CML and Ph+ ALL patients with T315I mutations, remains uncertain. Concerningly high rates of cardiovascular adverse events were also reported for nilotinib, although they have received less attention in the scientific and lay press (232, 233). This raises the important question how to weigh molecular efficacy against risks and side effects of treatment. The risk–benefit ratio of any given agent will be different in an elderly patient with cardiovascular risk factors or pre-existing disease with prolonged cardiovascular events were also reported for nilotinib, although they have received less attention in the scientific and lay press (232, 233). This raises the important question how to weigh molecular efficacy against risks and side effects of treatment. The risk–benefit ratio of any given agent will be different in an elderly patient with cardiovascular risk factors or pre-existing disease with highly intensive chemotherapy and radiation, both of which have been shown to independently affect longitudinal growth and bone health (237, 238).

**CURRENT AND FUTURE CLINICAL QUESTIONS**

**CHEMOTHERAPY BACKBONE**

In addition to the choice of TKI to be used in Ph+ ALL, several other critical questions regarding the optimal therapy for pediatric Ph+ ALL remain unresolved. The current highly intense chemotherapy backbones are associated with substantial treatment-related morbidity and mortality, as well as significant potential risk of late effects such as infertility and second malignancies. Furthermore, chemotherapy that is too intensive may compromise the ability to deliver optimal TKI therapy or to combine TKIs with other new targeted therapies. As discussed above, COG AALL1122, NCT01460160 is investigating dasatinib on the chemotherapy backbone of the AIEOP-BFM ALL 2000 regimen, which had shown excellent results in the EsPhALL trial. This backbone contains significantly reduced cumulative doses of cyclophosphamide, ifosfamide, etoposide, and high-dose methotrexate compared to AALL0031. Despite the changes, the morbidity and mortality associated with this regimen is still substantial. A successor trial in development proposes to compare the EsPhALL backbone to a less intensive chemotherapy regimen, with identical TKI therapy in the two regimens.

**DURATION OF TKI INHIBITION**

Another open question is the duration of TKI inhibition. Several current protocols in adult patients propose indefinite tyrosine kinase inhibition after completion of maintenance ALL therapy (Table 1). In contrast, the current pediatric Ph+ ALL trials typically stop TKI therapy when chemotherapy stops at 2–2.5 years post diagnosis. There have been some, but relatively few late events in COG AALL0031 suggesting that this approach is feasible and not associated with excessive relapses. However, it remains uncertain if additional TKI therapy beyond 2–2.5 years is beneficial. In particular, there are concerns about growth and bone mineral density with prolonged TKI therapy in children (234–236). These effects may be compounded by the concomitant use of highly intensive chemotherapy and radiation, both of which have been shown to independently affect longitudinal growth and bone health (237, 238).

**THE ROLE OF HEMATOPOIETIC STEM-CELL TRANSPLANT**

In AALL0031, HSCT did not improve outcomes for patients treated with imatinib in the final cohort. In contrast, outcomes for patients who did not undergo HSCT on EsPhALL appeared inferior to the transplanted cohort (relapse was reported in three of nine good-risk patients and five of seven poor-risk patients). It is possible that the longer duration of imatinib on AALL0031 (616 versus 126 days on EsPhALL) plays a role. On both trials, the numbers were extremely small, and more data will be required to define the role of HSCT in Ph+ ALL. The current combined follow-up study of AALL0031/AALL0062 and EsPhALL, AALL1122 (NCT01460160), is assessing the effect of earlier, continuous, and longer exposure to dasatinib. Rather than pursuing HSCT in all patients, only patients who fail to meet predefined MRD criteria and have a suitable donor are assigned to undergo HSCT in first remission, which is the approach generally pursued in other pediatric ALL subsets. In adult patients, initial studies were unable to address the question of whether HSCT confers a survival benefit due to small sample sizes, but durable remissions have been observed with the combination of TKI and intensive chemotherapy regimens (157, 159, 162). HSCT in first remission (if possible based on donor availability and clinical status of the recipient) remains the standard of care in younger adults with Ph+ ALL, but outstanding results observed with chemotherapy plus TKI are challenging this consensus. Despite controversy over the role of HSCT in first remission in pediatric Ph+ ALL, there is universal consensus that HSCT in second complete remission is the preferred therapy after relapse.

**THE ROLE OF POST-TRANSPLANT TKI**

Another open question centers on whether and for how long TKIs could or should be continued after HSCT. Several studies suggest that post-transplant TKI therapy is beneficial and reduce the rate of relapse (239–242). However, the duration of post-transplant TKI therapy varies widely between studies, and high rates of dose reduction and cessation due to cytophenias and other side effects have been reported. Very few prospective randomized studies are...
available. A recent GMALL study randomly assigned Ph+ ALL patient to receive imatinib post-HSCT either prophylactically, or triggered by a rise in MRD. Molecular recurrence after HSCT was significantly lower in the prophylactic group (40 versus 69%; \( P = 0.046 \)), although this did not translate into a difference in survival (243). In a recently reported non-randomized trial of 92 patients with Ph+ ALL, the ability to tolerate post-HSCT imatinib was an independent predictor of DFS and OS (244). This study involved pediatric patients, who had a higher rate of tolerating post-transplant imatinib than adult patients. In the current pediat-

CONCLUSION

Ph+ ALL is a poster child for the successful integration of small-molecule inhibitors with standard chemotherapy. TKIs have revolutionized the outcomes of this disease. However, survival rates are still inferior to most other types of childhood ALL. Future efforts to improve survival and decrease toxicity need to focus on refining chemotherapy regimens, and optimizing TKI therapy. In addition, increasing the mechanistic understanding of this complex and fascinating disease will facilitate translating new findings into improved targeted therapies.

ACKNOWLEDGMENTS

Stephen P. Hunger is the Ergen Family Chair in Pediatric Cancer. This manuscript is dedicated to Janet Rowley, who revolutionized understanding of cancer genetics.

REFERENCES

1. Mahon FX. Is going for cure in chronic myeloid leukemia possible and justifiable? Hematolgy Am Soc Hematol Educ Program (2012) 2012:228–8. doi:10.1182/asheducation-2012.1.222

2. Schultz KR, Bowman WP, Aledo A, Slattery WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol (2009) 27(31):5175–81. doi:10.1200/JCO.2008.21.2314

3. Ilaria RL Jr. Pathobiology of lymphoid and myeloid blast crisis and man-

4. Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 28(31):4755–61. doi:10.1200/JCO.2010.30.1325

5. Murozek K, Harper DP, Aplan PD. Cytogetenics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Am Soc Hematol Educ Program (2009) 23(5):991–1010. doi:10.1016/j.hjmo.2009.07.001

6. Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol (2006) 43(2):126–33. doi:10.1053/j.seminhematol.2006.01.007

7. Kelliker M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol (1991) 11(9):4710–6.

8. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247(4944):243–40. doi:10.1126/science.2408149

9. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature (1990) 344(6263):251–3. doi:10.1038/344251a0

10. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247(4946):1079–82. doi:10.1126/science.2408149

11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2(5):561–6. doi:10.1038/nm9596-561

12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Effi-
cacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 344(14):1036–42. doi:10.1056/NEJM200104053441402

13. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 344(14):1038–42. doi:10.1056/NEJM200104053441402

14. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-Phase chronic myeloid leukemia. N Engl J Med (2003) 348(11):994–1004. doi:10.1056/NEJMoa022547

15. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 362(24):2260–70. doi:10.1056/NEJMoa1002315

16. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 362(24):2251–9. doi:10.1056/NEJMoa1009164

17. Puttini M, Coluccia AM, Boscelli F, Clerici L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Ab1 inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res (2006) 66(23):13114–22. doi:10.1158/0008-5472.CAN-06-1199

18. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Pugette R, Chau C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 369(1):1783–96. doi:10.1056/NEJMoa1306494

19. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst (1960) 25:85–109.

20. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myel-

21. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromo-

22. L.S. Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 189(9):3399–412. doi:10.1083/jem.189.9.1399

23. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL onco-

24. Suryanarayanan K, Hunger SP, Kohler S, Carroll AJ, Crist W, Link MP, et al. Consistent involvement of the bcr gene by 9:22 breakpoints in pediatric acute leukemia. Blood (1991) 77(2):324–30.

25. Franz WM, Berger P, Wang YJ. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J (1989) 8(1):137–47.

26. Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 3(5):436–46. doi:10.1177/1947601912458584

27. McWhirter JR, Galasso DL, Wang YJ. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol (1993) 13(12):2587–95.

28. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK, et al. The coiled-coil domain and Tryrl177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood (2002) 99(8):2957–68. doi:10.1182/blood.V99.8.2957

29. Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myelogenous leukemia-like disease in mice by the Bcr/Ab1 tyrosine kinase. Blood (2000) 96(2):664–70.

30. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activ-

31. Muller AJ, Young JC, Pendergast AM, Pendel M, Landas NR, Littman DR, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase
oncogene of Philadelphia chromosome-positive human leukemias. *Mol Cell Biol* (1991) 11(4):1785–92.

32. Pendergast AM, Muller AJ, Halik M, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. *Cell* (1991) 66(1):161–71. doi:10.1016/0092-8674(91)90148-R

33. Beissert T, Hündertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, et al. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR-ABL. *Int J Cancer* (2008) 122(12):2742–54. doi:10.1002/ijc.23467

34. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR-ABL. *Leukemia* (2009) 23(12):2242–7. doi:10.1038/leu.2009.194

35. Zhang J, Adrian FJ, Jahneke W, Cowan-Jacob SW, Li AG, Iacobu RE, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. *Nature* (2010) 463(7280):501–6. doi:10.1038/nature08675

36. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. *Nat Chem Biol* (2006) 2(2):95–102. doi:10.1038/nchembio760

37. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. *Semin Hematol* (2003) 40(2 Suppl 2):1–40. doi:10.1053/shem.2003.50034

38. Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, et al. BCR/ABL kinase inhibition by dasatinib treatment differs in patients with newly diagnosed and recurrent bcr-abl-positive acute lymphoblastic leukemia CD34+ cells. *J Clin Oncol* (2003) 21(15):3167–74. doi:10.1097/01耗费.2003.04.1271

39. Chu S, Holtz M, Gupta M, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. *Cancer Res* (2007) 67(14):7045–53. doi:10.1158/0008-5472.CAN-06-4312

40. Chu S, Li L, Singh H, Bhatia R. mTOR inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. *Eur J Haematol* (2014) 92(2):111–20. doi:10.1111/ejh.12102

41. Piovan E, Yu J, Tosello V, Herranz D, Ambessi-Impimbiardi A, Da Silva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. *Cancer Cell* (2013) 24(6):766–76. doi:10.1016/j.ccr.2013.10.022

42. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. *Cancer Cell* (2006) 10(3):331–42. doi:10.1016/j.ccr.2006.09.006

43. Barrett D, Brown VI, Grupp SA, Teachey DT. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. *Paediatr Drugs* (2012) 14(5):299–316. doi:10.2165/11594740-000000000-00000

44. Cheng AM, Saxton TM, Sakai R, Kulkarni S, Mbamalu G, Vogel W, et al. Mamalian Grb2 regulates multiple steps in embryonic development and malignant transformation. *Cell* (1998) 95(6):793–803. doi:10.1016/S0092-8674(00)8022-X

45. Kardinal C, Konkol B, Lin H, Eulitiz M, Schmidt EK, Estrov Z, et al. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-Sox complexes. *Blood* (2001) 98(6):1773–81. doi:10.1182/blood-2001-V89.6.1773

46. Lewitzky M, Kardinal C, Gehring NH, Schmidt EK, Eulitiz M, et al. The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif. *Oncogene* (2001) 20(9):1052–62. doi:10.1038/sj.onc.1204202

47. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb2-2 adaptor protein. *Cell* (1993) 75(1):175–85. doi:10.1016/0092-8674(93)90689-N

48. Redig AJ, Vakana E, Platinias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. *Leuk Lymphoma* (2011) 52(Suppl 1):1–43. doi:10.3109/10428194.2010.56919

49. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. *Cell* (1995) 82(6):981–8. doi:10.1016/0092-8674(95)90277-5

50. Modri H, Li L, Chu S, Ross J, Yee JK, Bhatia R. Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. *Leukemia* (2011) 25(2):305–12. doi:10.1038/leu.2010.257

51. Hoell S, Kovacic B, Kerenyi MA, Simma O, Warnich W, Cui Y, et al. Clarifying the role of Stat5c in lymphoid development and Ablon-induced transformation. *Blood* (2006) 107(12):4298–90. doi:10.1182/blood-2005-09.3956

52. Hu Y, Liu Y, Pelletier S, Buschunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. *Nat Genet* (2004) 36(5):543–61. doi:10.1038/ng1343

53. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, activation of Stat3 and Stat4 with tyrosine phosphorylated Stats. *Leukemia* (1996) 10(11):1724–30.

54. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr-Abl. *J Exp Med* (1996) 183(3):811–20. doi:10.1084/jem.183.3.811

55. Ilaria RJ, Jr, Van Etten RA, P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. *J Biol Chem* (1996) 271(49):31704–10. doi:10.1074/jbc.271.49.31704

56. Tao WJ, Lin H, Sun T, Samanta AK, Aflarshingh R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. *Oncogene* (2008) 27(22):3194–200. doi:10.1038/21210979

57. Samanta A, Perazzoza B, Chakraborty S, Sun X, Modi H, Bhatia R, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. *Leukemia* (2011) 25(3):463–72. doi:10.1038/leu.2010.287

58. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley MW, Pestman J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res* (2005) 65(11):4500–5. doi:10.1158/0008-5472.CAN-05-0259

59. Yen X, He G, Gong Y, Zheng B, Shi F, Shi R, et al. mTOR inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. *Eur J Haematol* (2014) 92(2):111–20. doi:10.1111/ejh.12102

---

**Bernt and Hunger**

Pediatric Ph+ acute lymphoblastic leukemia

---

**www.frontiersin.org**

March 2014 | Volume 4 | Article 54 | 15
105. Ng SY, Yoshida T, Zhang J, Geogopoulos K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. *Immunity* (2009) 30(4):493–507. doi:10.1016/j.immuni.2009.01.014

106. Malin S, McManus S, Busslinger M. STAT5 in B cell development and leukemia. *Curr Opin Immunol* (2010) 22(2):168–76. doi:10.1016/j.coi.2010.02.004

107. Ramirez J, Lukin K, Hagman J. From hematopoietic progenitors to B cells: mechanisms of lineage restriction and commitment. *Curr Opin Immunol* (2010) 22(2):177–84. doi:10.1016/j.coi.2010.02.003

108. Boggs SS, Trevisan M, Patrene K, Geogopoulos K. Lack of natural killer cell precursors in fetal liver of Ikaros knockout mutant mice. *Nat Immun* (1998) 16(4):137–45. doi:10.1038/40069438

109. Winandy S, Wu P, Geogopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. *Cell* (1995) 83(2):289–99. doi:10.1016/0092-8674(95)90170-1

110. Kastner P, Chan S. Role of Ikaros in T-cell acute lymphoblastic leukemia. *Immunity* (2006) 25(5):524–6. doi:10.1016/j.immuni.2006.05.096

111. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. *Immunobiology* (1997) 197(1–3):227–35. doi:10.1016/S0941-9397(97)80403-5

112. Kirstetter P, Thomas M, Dierich A, Kastner P, Chan S. Ikaros is critical for B cell differentiation and function. *Eur J Immunol* (2002) 32(3):720–30. doi:10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P

113. Maloney KW, McGavran L, Odom LF, Hunger SP. Different patterns of homozygous p11NKA4 and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations. *Leukemia* (1998) 12(9):1417–21. doi:10.1038/leu.2001124

114. Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Ehrorn A, et al. Genome commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. *Haematologica* (2013) 98(7):1018–8. doi:10.3324/haematol.2013.085175

115. Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. *Genes Dev* (2008) 22(11):1411–5. doi:10.1101/gad.1673908

116. Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B, et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. *Cancer Genet Cytogenet* (2009) 195(1):59–65. doi:10.1016/j.cancergen.2009.06.013

117. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. *Blood* (1995) 85(1):2013–6.

118. Kolho T, Yokota J. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions. *DNA Repair* (2006) 5(9):1073–81. doi:10.1016/j.dnarep.2006.05.021

119. Williams RT, Rousset MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits inactivating response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A* (2006) 103(17):6888–93. doi:10.1073/pnas.0602030103

120. Nakanuma M, Sugita K, Inukai T, Goti K, Iijima K, Terzuka T, et al. p16/MTS1/INK4A genes is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. *Leukemia* (1999) 13(6):884–90. doi:10.1038/sj.leu.2401437

121. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagues JM, Espinosa AB, et al. Genetic heterogeneity of BCR-ABL1+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypic disease characteristics. *Leukemia* (2005) 19(5):713–20. doi:10.1038/sj.leu.2403714
145. Carter TL, Watt PM, Kumar R, Burton PR, Reaman GH, Sather HN, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood (2001) 99(7):572–4. doi:10.1182/blood.V99.7.572

146. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian H, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res (2002) 8(7):2217–24.

152. Eads CA, Nickel AE, Laird PW. Complete genetic suppression of polyp formation and reduction of CpG island hypermethylation in Apc(Min/+1) Dnmt1-hypomorphic Mice. Cancer Res (2002) 62(5):1296–9.

159. Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (2007) 110(2):727–34. doi:10.1182/blood-2006-11-052573

163. Delaney O, Delabesse E, Lhermitte V, Castaigne S, Rigal-Huguet F, Raffoux E, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFRO9 study. Leukemia (2006) 20(9):1526–32. doi:10.1038/sj.leu.2404320

164. Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gokbuget N, Atta J, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood (2004) 103(4):1495–8. doi:10.1182/blood-2003-01-0154

165. Jones D, Thomas D, Yin CC, O’Brien S, Cortes JE, Jabbour E, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer (2008) 113(5):985–94. doi:10.1182/cancer.2008-2366

170. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphoblastic leukemia. Clin Cancer Res (2002) 8(7):2295–304. doi:10.1182/1078-0432.CCR-11-1227

171. Soverini S, Colarossi S, Gnani A, Rossi G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res (2006) 12(24):7374–9. doi:10.1158/1078-0432.CCR-06-1516

180. Bernt and Hunger Pediatric Ph+ acute lymphoblastic leukemia

Pediatric Ph+ acute lymphoblastic leukemia

Frontiers in Oncology | Pediatric Oncology

March 2014 | Volume 4 | Article 54 | 18
Burger H, van Tol H, Boersma AW, Brok M, Wiemers EA, Stoter G, et al. Imaging of VHL disease: a new perspective in the breast cancer resistance protein (BCRP/ABCG2) drug pump. Blood (2004) 104(9):2940–2. doi:10.1182/blood-2004-04-1398

Ramakers-van Woerden NL, Pieters R, Hoelzer D, Slater RM, den Boer ML, Loonen AH, et al. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol (2002) 38(6):379–86. doi:10.1002/mpo.10087

Mahon FX, Hayette S, Lagarde V, Belloir F, Turcq B, Nicolini F, et al. Evidence that resistance to nitrosobenzene may be due to BCR-ABL, Pbg, or Sc kinase overexpression. Cancer Res (2008) 68(23):9809–16. doi:10.1158/0008-5472.CAN-08-1088

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bormann WG, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of Lyn kinase. J Natl Cancer Inst (2008) 100(13):926–39. doi:10.1093/jnci/djn188

Donato NJ, Wu LY, Staple J, Gallicic G, Lin H, Arlinghaus R, et al. BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 101(2):980–8. doi:10.1182/blood.V101.2.980

Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB. Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ONO45450 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Genes Cancer (2010) 1(4):346–59. doi:10.1177/1947619110327223

Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, et al. Tarpomycin-based chimeric antigen receptor T-cell therapy in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2012) 120(17):3510–8. doi:10.1182/blood-2012-03-541448

Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, et al. A signaling pathway mediating downregulation of BCL6 in terminal center B-cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell (2007) 12(3):283–90. doi:10.1016/j.ccr.2007.08.011

Walker SR, Nelson EA, Frank DA. STAT3 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene (2007) 26(22):2244–33. doi:10.1038/sj.onc.1209775

Fernandez-de Mattos S, Esaul S, Soeiro I, Pietersen AM, Birkenkamp-Ku KM, Edwards CS, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 24(22):10058–71. doi:10.1128/MCB.24.22.10058-10071.2004

Duy C, Hultz C, Sjoaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 473(7347):384–8. doi:10.1038/nature09883

Hurtz C, Hatsi K, Cerchietti L, Brag M, Park E, Kim YM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 208(11):2163–74. doi:10.1084/jem.20110304

Nahar R, Ramezanlai-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, et al. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood (2011) 118(14):4174–6. doi:10.1182/blood-2011-01-33181

Chevallier P, Robillard N, Wullemme-Toumi S, Mechinadn F, Harousseau JL, Avet-Loiseau H. Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. Haematologica (2004) 89(11):1399–401.

Kasper RP, Waanders E, van der Velden VH, van Reijnengelsd SV, Venkatcha- larn R, Scheijen B, et al. BCRP1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia (2010) 24(7):1258–64. doi:10.1038/leu.2010.87

Mullighan CG, Phillips LA, Su X, Ma J, Miller CR, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 322(5906):1377–80. doi:10.1126/science.1164266

Epker N, Takanaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 17(9):1086–93. doi:10.1038/nm.2415

Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 304(24):2706–15. doi:10.1001/jama.2010.1862
229. Usuki K, T ojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, et al. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant chronic myeloid leukemia: a phase I and II study. *Int J Hematol* (2012) 95(4):409–19. doi:10.1007/s11215-012-1026-9

230. Castillo E, Al-Rajabi R, Pandya DM, Varadarajan P, Kelly KR, Swords R, et al. A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia. *Blood* (2010) 116:885–6.

231. Kim D-Y, Joo YD, Kim S-D, Lee J-H, Lee J-H, Kim D-H, et al. Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphocytic leukemia: final results of prospective multicenter Phase 2 study. *Blood* (2010) 55.

232. Tettieri A. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? *Leukemia* (2013) 27(9):1939–40. doi:10.1038/leu.2013.112

233. Coon EA, Zaleswki NL, Hoffman EM, Tettieri A, Flemming KD. Nilotinib treatment-associated cerebrovascular disease and stroke. *Int J Hematol* (2013) 88(6):534–5. doi:10.1002/ijh.23442

234. Berman E, Nicolasdes M, Maki RG, Fleisher M, Chanal S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. *N Engl J Med* (2006) 354(19):2006–13. doi:10.1056/NEJMoa051140

235. Atkinson SA, Halton JM, Bradley C, Wu B, Barr RD. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition. *Int J Cancer Suppl* (1998) 11:15–9. doi:10.1002/sic.1097-0215(1998)78:1+<35::AID-IJC11>3.3.CO;2-9

236. Hobernicht SL, Schweiger B, Zeiterl P, Wang M, Hunger SP. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. *Pediatr Blood Cancer* (2011) 56(4):671–3. doi:10.1002/pbc.22945

237. Greenberg N, Haddad R, Ackerman N, Sallan S, Finley JL, Grunhut J, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. *Blood* (2009) 114(7):2391–9. doi:10.1182/blood-2008-09-195064

238. Eicher GM, Trott J, Scanga CA, Gribben JG, Schmitz N, Lechner C, et al. Allogeneic hematopoietic cell transplantation in chronic myelogenous leukemia patients with secondary CML: a prospective multicenter phase 2 study. *Blood* (2007) 109:2791–3. doi:10.1182/blood-2006-04-19836

239. Burke MJ, Trott B, Lao X, Weisdorf DJ, Baker RS, Wagner JE, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant and -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood* (2013) 122:2528–31. doi:10.1182/blood-2012-10-442816

240. Chirigos M, Sallan S, Finley JL, Trott J, Haddad R, Ackerman N, et al. Activity of bosutinib, nilotinib, and dasatinib in relapsed or refractory chronic myelogenous leukemia: a pooled phase 2 analysis. *Leukemia* (2014). doi:10.1038/leu.2014.30

241. Burke MJ, Trott B, Lao X, Weisdorf DJ, Baker RS, Wagner JE, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. *N Engl J Med* (2006) 354(19):2006–13. doi:10.1056/NEJMoa051140

242. Greenberg N, Haddad R, Ackerman N, Sallan S, Finley JL, Grunhut J, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. *Blood* (2009) 114(7):2391–9. doi:10.1182/blood-2008-04-19836

243. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, et al. Nilotinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. *Blood* (2007) 110(7):2309–15. doi:10.1182/blood-2007-02-073528

244. Ravaud F, O’Brien S, Thomas D, Faderl S, Jones D, Garrir R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. *Blood* (2010) 116(12):2070–7. doi:10.1182/blood-2009-12-261586

245. Benjamini O, Dumlao TL, Kantarjian H, O’Brian S, Garcia-Manero G, Faderl S, et al. Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphocytic leukemia or blast phase chronic myeloid leukemia. *Am J Hematol* (2013) 88(3):282–7. doi:10.1002/ajh.23624

246. Zwaan CM, Rizzi C, Mechinaud F, Lancaster DL, Lehnbrecher T, van der Velden VH, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase 1 dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. *J Clin Oncol* (2013) 31(19):2460–8. doi:10.1200/JCO.2012.46.8280

247. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children’s Oncology Group Phase I Consortium. *J Clin Oncol* (2011) 29(7):839–44. doi:10.1200/JCO.2010.30.2321

248. Slattery WB, Schulz KR, Jones T. Continuous dose dasatinib is safe and feasible in combination with intensive chemotherapy in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): Children’s Oncology Group (COG) Trial AALL0622. *Blood* (2012) 120:137.

249. Slattery WB, Schulz KR, Jones T, Devidas M, Raetz WB, Sorror ML, et al. Nilotinib induces rapid hematologic and cytogenetic responses in pediatric Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL): Children’s Oncology Group (COG) trial AALL0622. *Pediatr Blood Cancer* (2012) 59:988.

250. Ottmann OG, Larsson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, et al. Phase II study of nilotinib in patients with relapsed or refractory chronic myelogenous leukemia - positive acute lymphoblastic leukemia. *Leukemia* (2013) 27(6):1411–3. doi:10.1038/leu.2012.324

251. Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, et al. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. *Int J Hematol* (2012) 95(4):409–19. doi:10.1007/s11215-012-1026-9
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.